In this post-hoc analysis of data from a larger clinical trial (Winhusen et al., 2010), we examined the effects of OROS-MPH on weight gain in adult selleck chemicals Imatinib Mesylate smokers with ADHD who were enrolled in a smoking-cessation study. We hypothesized that relative to placebo plus NRT and counseling, OROS-MPH plus NRT and counseling would be associated with less weight gain, as well as attenuation of the increased hunger that commonly accompanies efforts to quit smoking. Methods Participants Participants were 215 treatment-seeking adult smokers with ADHD who completed a multisite study examining the effects of OROS-MPH for smoking cessation (NCT #00253747), as an adjunct to transdermal nicotine replacement and brief counseling.

Participants were between 18 and 55 years of age; in good physical health; smoking at least 10 cigarettes per day, with an expired carbon monoxide level �� 8 ppm; smoked for at least 3 months; and had a DSM-IV ADHD Rating Scale score > 22. Exclusion criteria were current non-nicotine substance abuse or dependence; current mood or anxiety disorders (except specific phobia); lifetime antisocial personality disorder or psychosis; personal history of narrow angle glaucoma, tics, or a seizure disorder; family history of Tourette syndrome; positive screen for illicit drug use; having received pharmacotherapy or behavioral treatment for smoking cessation in the prior 30 days; current use of tobacco products other than cigarettes; having received pharmacotherapy for ADHD in the prior 30 days; prior unsuccessful treatment with methylphenidate for ADHD; significant suicidal/homicidal risk; for women, pregnancy, breastfeeding, or refusal to use an approved means of contraception; allergies to OROS-MPH; and use of a monoamine oxidase inhibitor in the prior 14 days.

For safety reasons, blood pressure readings greater than 130/80 and/or a heart rate more than 88 beats per minute on two clinic visits were exclusionary for individuals of age 40�C55. If less than 40 years old, blood pressure readings greater than 135/85 and/or heart rate more than 90 beats per minute on two clinic visits were exclusionary. Assessments ADHD diagnosis and severity were determined using the Adult ADHD Clinical Diagnostic Scale (Adler & Spencer, 2004) and the DSM-IV ADHD Rating Scale (DuPaul et al., 1998), respectively. The Composite International Diagnostic Interview (CIDI; Robins et al.

, 1988) was also administered at screening by a trained rater to determine whether psychiatric Entinostat inclusion/exclusion criteria were met. Medical history and physical examination were performed by a certified clinician, and demographic and smoking history information were obtained by a trained research assistant. Participants completed the Fagerstr?m Test for Nicotine Dependence (FTND; Heatherton, Kozlowski, Frecker, & Fagerstr?m, 1991) at baseline as a measure of severity of nicotine dependence.